Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Common Equity (2020 - 2025)

Oncology Institute (TOI) has disclosed Common Equity for 6 consecutive years, with -$12.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Common Equity fell 179.28% year-over-year to -$12.3 million, compared with a TTM value of -$12.3 million through Sep 2025, down 179.28%, and an annual FY2024 reading of $3.6 million, down 93.71% over the prior year.
  • Common Equity was -$12.3 million for Q3 2025 at Oncology Institute, down from -$9.0 million in the prior quarter.
  • Across five years, Common Equity topped out at $132.0 million in Q1 2022 and bottomed at -$12.3 million in Q3 2025.
  • Average Common Equity over 5 years is $60.1 million, with a median of $50.4 million recorded in 2021.
  • The sharpest move saw Common Equity skyrocketed 386.22% in 2021, then tumbled 179.28% in 2025.
  • Year by year, Common Equity stood at $104.2 million in 2021, then increased by 18.26% to $123.2 million in 2022, then tumbled by 53.7% to $57.0 million in 2023, then crashed by 93.71% to $3.6 million in 2024, then crashed by 441.99% to -$12.3 million in 2025.
  • Business Quant data shows Common Equity for TOI at -$12.3 million in Q3 2025, -$9.0 million in Q2 2025, and $5.1 million in Q1 2025.